Nerandomilast for Progressive Pulmonary Fibrosis | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Nerandomilast for Progressive Pulmonary Fibrosis
Related Articles
Medical Mystery Solved — A Burning Question | NEJM
This Double Take video from the New England Journal of Medicine describes the case of a 35-year-old man presenting with 4 years of shortness of…
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis | NEJM
Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with…
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …
Cardiac Injury Detected by Smartwatch | NEJM
A 76-year-old retired cardiovascular nurse presented to the ED with 2 hours of chest pain triggered by severe emotional distress and associated with changes in…
Addressing Antifungal Drug Resistance — A “One Health–One World” Challenge | NEJM
Use of some antifungal pesticides may select for resistant fungi in the environment, which can then endanger human health. Coordinated regulatory processes in this area…
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B | NEJM
Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B. Data on safety and durability from 13 years of follow-up in…
Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin | NEJM
Allogeneic peripheral-blood stem-cell transplantation (SCT) from a matched related donor after myeloablative conditioning is the preferred curative treatment for patients with high-risk blood cance…
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma | NEJM
Measurable residual disease (MRD) is a major prognostic factor in newly diagnosed multiple myeloma. An assessment of an MRD-guided consolidation strategy in patients who are…
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia | NEJM
An interim analysis of progression-free survival in this trial showed that ibrutinib–venetoclax was superior to fludarabine–cyclophosphamide–rituximab (FCR) among patients with chronic lymphocytic …